In animal models of obesity, the administration of this dual GLP-1R/GCGR agonists resulted in better weight loss, lower glucose levels, and reduced food intake, compared to pure GLP-1r agonists alone [142,143,144]. The gene discussed is GLP1R; the disease is obesity disorder.